{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+Squamous%2C+Non-small-cell+Lung+Cancer&page=21", "query": { "condition": "Non Squamous, Non-small-cell Lung Cancer", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 750, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+Squamous%2C+Non-small-cell+Lung+Cancer&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non+Squamous%2C+Non-small-cell+Lung+Cancer&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:36:54.224Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02834013", "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acinar Cell Carcinoma", "Adenoid Cystic Carcinoma", "Adrenal Cortical Carcinoma", "Adrenal Gland Pheochromocytoma", "Anal Canal Neuroendocrine Carcinoma", "Anal Canal Undifferentiated Carcinoma", "Angiosarcoma", "Apocrine Neoplasm", "Appendix Mucinous Adenocarcinoma", "Bartholin Gland Transitional Cell Carcinoma", "Basal Cell Carcinoma", "Bladder Adenocarcinoma", "Breast Metaplastic Carcinoma", "Cervical Adenocarcinoma", "Cholangiocarcinoma", "Chordoma", "Colorectal Squamous Cell Carcinoma", "Desmoid Fibromatosis", "Endometrial Transitional Cell Carcinoma", "Endometrioid Adenocarcinoma", "Esophageal Neuroendocrine Carcinoma", "Esophageal Undifferentiated Carcinoma", "Extrahepatic Bile Duct Carcinoma", "Extramammary Paget Disease", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fibromyxoid Tumor", "Gallbladder Carcinoma", "Gastric Neuroendocrine Carcinoma", "Gastric Squamous Cell Carcinoma", "Gastric Undifferentiated Carcinoma", "Gastrointestinal Stromal Tumor", "Gestational Trophoblastic Tumor", "Giant Cell Carcinoma", "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type", "Intestinal Neuroendocrine Carcinoma", "Intrahepatic Cholangiocarcinoma", "Lung Neuroendocrine Tumor", "Lung Sarcomatoid Carcinoma", "Major Salivary Gland Carcinoma", "Malignant Neoplasm of Unknown Primary", "Malignant Odontogenic Neoplasm", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Solid Neoplasm", "Malignant Testicular Sex Cord-Stromal Tumor", "Metastatic Pituitary Neuroendocrine Tumor", "Minimally Invasive Lung Adenocarcinoma", "Mixed Mesodermal (Mullerian) Tumor", "Mucinous Adenocarcinoma", "Mucinous Cystadenocarcinoma", "Nasal Cavity Adenocarcinoma", "Nasal Cavity Carcinoma", "Nasopharyngeal Carcinoma", "Nasopharyngeal Low Grade Papillary Adenocarcinoma", "Nasopharyngeal Undifferentiated Carcinoma", "Oral Cavity Carcinoma", "Oropharyngeal Undifferentiated Carcinoma", "Ovarian Adenocarcinoma", "Ovarian Germ Cell Tumor", "Ovarian Mucinous Adenocarcinoma", "Ovarian Squamous Cell Carcinoma", "Ovarian Transitional Cell Carcinoma", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Neuroendocrine Carcinoma", "Paraganglioma", "Paranasal Sinus Adenocarcinoma", "Paranasal Sinus Carcinoma", "Parathyroid Gland Carcinoma", "PEComa", "Penile Squamous Cell Carcinoma", "Peritoneal Mesothelial Neoplasm", "Placental Choriocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Pseudomyxoma Peritonei", "Rare Disorder", "Scrotal Squamous Cell Carcinoma", "Seminal Vesicle Adenocarcinoma", "Seminoma", "Serous Cystadenocarcinoma", "Small Intestinal Adenocarcinoma", "Small Intestinal Squamous Cell Carcinoma", "Spindle Cell Neoplasm", "Teratoma With Somatic-Type Malignancy", "Testicular Non-Seminomatous Germ Cell Tumor", "Thyroid Gland Carcinoma", "Tracheal Carcinoma", "Transitional Cell Carcinoma", "Ureter Adenocarcinoma", "Ureter Squamous Cell Carcinoma", "Urethral Adenocarcinoma", "Urethral Squamous Cell Carcinoma", "Vaginal Adenocarcinoma", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 798, "start_date": "2017-01-30", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 1006, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02834013" }, { "nct_id": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer", "Non-small Cell Lung Cancer", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GB1275", "type": "DRUG" }, { "name": "nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-08-13", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060342" }, { "nct_id": "NCT05256290", "title": "Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Advanced Non-Small Cell Squamous Lung Cancer", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "NSCLC", "Advanced Lung Carcinoma", "Epidermal Growth Factor Receptor C797S", "Epidermal Growth Factor Receptor G719X", "EGF-R Positive Non-Small Cell Lung Cancer", "EGFR-TKI Resistant Mutation" ], "interventions": [ { "name": "silevertinib (BDTX-1535) monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Black Diamond Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2022-03-31", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05256290" }, { "nct_id": "NCT06159790", "title": "A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic NSCLC" ], "interventions": [ { "name": "GME751", "type": "DRUG" }, { "name": "Keytruda-EU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sandoz", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2024-04-29", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 1, "location_summary": "Fountain Valley, California", "locations": [ { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06159790" }, { "nct_id": "NCT02019979", "title": "Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer Stage IIIB/IV", "Non-small Cell Lung Cancer Metastatic", "Nonsquamous Nonsmall Cell Neoplasm of Lung" ], "interventions": [ { "name": "metformin", "type": "DRUG" }, { "name": "carbohydrate restricted diet", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Beth Israel Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2013-12", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-05-04", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 4, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02019979" }, { "nct_id": "NCT00356122", "title": "Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2006-07", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2011-10-17", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00356122" }, { "nct_id": "NCT07489066", "title": "Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma", "Non-Small-Cell Lung", "Lung Cancer (NSCLC)", "Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung (NSCLC)", "Lung Disease", "Non-Small Cell Lung Cancer", "Non-small Cell Lung Cancer, Non-squamous", "Non-small Cell Lung Cancer, Squamous" ], "interventions": [ { "name": "PF-08634404", "type": "BIOLOGICAL" }, { "name": "Chemotherapy Regimen 1", "type": "DRUG" }, { "name": "Chemotherapy Regimen 2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2026-06-30", "completion_date": "2031-07-30", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 15, "location_summary": "Huntsville, Alabama • Stanford, California • Athens, Georgia + 7 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07489066" }, { "nct_id": "NCT03849469", "title": "A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Cervical Carcinoma", "Pancreatic Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced or Metastatic Solid Tumors", "Prostate Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Intrahepatic Cholangiocarcinoma", "Squamous Cell Anal Cancer", "Squamous Cell Penile Carcinoma", "Squamous Cell Vulvar Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma" ], "interventions": [ { "name": "XmAb®22841", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (Keytruda®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-05-29", "completion_date": "2023-02-16", "has_results": false, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 28, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03849469" }, { "nct_id": "NCT06246110", "title": "A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "EIK1001", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eikon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2024-02-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 38, "location_summary": "Daphne, Alabama • Chandler, Arizona • Fresno, California + 33 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06246110" }, { "nct_id": "NCT05005403", "title": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Micro Satellite Stable Colorectal Cancer", "Gastric/Esophageal Cancer", "High-Grade Serous Ovarian Cancer", "Pancreatic Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Azirkitug", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Telisotuzumab Adizutecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 694, "start_date": "2021-11-01", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-15T12:36:54.224Z", "location_count": 20, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05005403" } ] }